title: Bleeding issues in neonates and infants - update 2015.
abstract: The presentation of a neonate with clinical bleeding symptoms commonly causes considerable anxiety to parents and treating physicians. Since inherited coagulation disorders are rare many children with persistently abnormal coagulation screens will have an underlying bleeding disorder. Apart from emergency cases a family history including a bleeding questionnaire is mandatory asking for the onset and/or severity symptoms of hemorrhage prior to laboratory assessment. The absolute values of reference ranges for coagulation assays in neonates and children vary with analyzer and reagent systems, but confirm the concept of developmental hemostasis, showing that physiologic concentrations of coagulation proteins gradually increase and are lower in premature infants as compared to full-term babies or healthy children. The evaluation should include global screening tests and a full blood cell count to rule out thrombocytopenia. As in adults a prolonged PT in neonates reflects decreased plasma concentrations of vitamin-K-dependent factors, whereas the prolonged PTT stems from decreased plasma levels of contact factors. When initial laboratory test results reveal abnormalities, as compared to age-related values, a stepwise diagnostic approach should be followed. In the bleeding neonate or infant that has no laboratory abnormality, FXIII and alpha2-antiplasmin activity should be assessed, and when primary hemostatic defects are suspected, platelet function should be further evaluated. Treatment options of a bleeding neonate vary according to the underlying medical condition.
authors.affiliation: University Hospital Schleswig-Holstein, Institute of Clinical Chemistry, Thrombosis & Hemostasis Treatment Center, Campus Kiel & Lubbock, Germany. Electronic address: leagottl@uksh.de.
authors.forename: Ulrike
authors.initials: U
authors.lastname: Nowak-Göttl
authors.affiliation: University Hospital Schleswig-Holstein, Institute of Clinical Chemistry, Thrombosis & Hemostasis Treatment Center, Campus Kiel & Lubbock, Germany.
authors.forename: Verena
authors.initials: V
authors.lastname: Limperger
authors.affiliation: University Hospital Schleswig-Holstein, Institute of Clinical Chemistry, Thrombosis & Hemostasis Treatment Center, Campus Kiel & Lubbock, Germany.
authors.forename: Alexander
authors.initials: A
authors.lastname: Bauer
authors.affiliation: University Hospital Schleswig-Holstein, Institute of Clinical Chemistry, Thrombosis & Hemostasis Treatment Center, Campus Kiel & Lubbock, Germany.
authors.forename: Dorothee
authors.initials: D
authors.lastname: Kowalski
authors.affiliation: Pediatric Coagulation Service, National Hemophilia Center, Institute of Thrombosis and Hemostasis, Sheba Medical Centre, Tel-Hashomer, Israel.
authors.forename: Gili
authors.initials: G
authors.lastname: Kenet
mesh_terms: D000933:Antifibrinolytic Agents / Q000627:therapeutic use*; D001780:Blood Coagulation Tests / Q000379:methods*; D006470:Hemorrhage / Q000151:congenital / Q000175:diagnosis* / Q000628:therapy*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D010808:Physical Examination / Q000379:methods*; D014812:Vitamin K / Q000627:therapeutic use*
chemical_list: D000933:Antifibrinolytic Agents; D014812:Vitamin K
keywords: Bleeding disorders; Developmental hemostasis; Neonates